PDGFRA and systemic sclerosis: Anti-PDGFRα autoantibodies play a role in the pathogenesis of scleroderma since they convert in vitro normal fibroblasts into SSc-like cells via the ROS, RAS, and ERK 1/2 pathway (23–26) and are capable to induce fibrosis in vivo (27).